Toll Free: 1-888-928-9744

Anaplastic Astrocytoma - Pipeline Review, H2 2017

Published: May, 2017 | Pages: 150 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Anaplastic Astrocytoma - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astrocytoma - Pipeline Review, H2 2017, provides an overview of the Anaplastic Astrocytoma (Oncology) pipeline landscape.

Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among men and women in their thirties to fifties and is more common in men than women. Treatment of anaplastic astrocytoma depends on the location of the tumor and how far it has progressed and usually involves surgery and radiation therapy, with chemotherapy during or following radiation. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaplastic Astrocytoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaplastic Astrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Unknown stages are 4, 8, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 2 molecules, respectively.

Anaplastic Astrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Anaplastic Astrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anaplastic Astrocytoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anaplastic Astrocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anaplastic Astrocytoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anaplastic Astrocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Anaplastic Astrocytoma - Overview 8 Anaplastic Astrocytoma - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 13 Products under Development by Companies 14 Products under Development by Universities/Institutes 16 Anaplastic Astrocytoma - Therapeutics Assessment 17 Assessment by Target 17 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Anaplastic Astrocytoma - Companies Involved in Therapeutics Development 26 Advantagene Inc 26 Alfa Wassermann SpA 26 Amgen Inc 27 AngioChem Inc 27 Astellas Pharma Inc 28 Bayer AG 28 Boehringer Ingelheim GmbH 29 Burzynski Research Institute Inc 29 Cavion LLC 30 Celldex Therapeutics Inc 30 Merrimack Pharmaceuticals Inc 31 Millennium Pharmaceuticals Inc 31 Novartis AG 32 Orbus Therapeutics Inc 32 Pfizer Inc 33 Tocagen Inc 33 Tragara Pharmaceuticals Inc 34 TVAX Biomedical Inc 34 ZIOPHARM Oncology Inc 35 Anaplastic Astrocytoma - Drug Profiles 36 (A-10 + AS-21) - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 AdRTSIL-12 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 afatinib dimaleate - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 alisertib - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 BAY-1436032 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 bendamustine hydrochloride - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 CDX-1401 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 Cellular Immunotherapy for Gliomas - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 Cellular Immunotherapy for Oncology - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 eflornithine hydrochloride - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 flucytosine + TBio-01 - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 flucytosine ER + vocimagene amiretrorepvec - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 G-207 - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 GliAtak - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 irinotecan hydrochloride - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 irinotecan hydrochloride + TBio-02 - Drug Profile 105 Product Description 105 Mechanism Of Action 105 R&D Progress 105 M-032 - Drug Profile 107 Product Description 107 Mechanism Of Action 107 R&D Progress 107 mibefradil dihydrochloride - Drug Profile 108 Product Description 108 Mechanism Of Action 108 R&D Progress 108 nilotinib - Drug Profile 111 Product Description 111 Mechanism Of Action 111 R&D Progress 111 p28 - Drug Profile 117 Product Description 117 Mechanism Of Action 117 R&D Progress 117 paclitaxel trevatide - Drug Profile 119 Product Description 119 Mechanism Of Action 119 R&D Progress 119 palbociclib - Drug Profile 124 Product Description 124 Mechanism Of Action 124 R&D Progress 124 procarbazine hydrochloride - Drug Profile 137 Product Description 137 Mechanism Of Action 137 R&D Progress 137 TBX.OncV NSC - Drug Profile 138 Product Description 138 Mechanism Of Action 138 R&D Progress 138 TG-02 - Drug Profile 139 Product Description 139 Mechanism Of Action 139 R&D Progress 139 TOT-302 - Drug Profile 142 Product Description 142 Mechanism Of Action 142 R&D Progress 142 TVI-Brain-1 - Drug Profile 143 Product Description 143 Mechanism Of Action 143 R&D Progress 143 Anaplastic Astrocytoma - Dormant Projects 145 Anaplastic Astrocytoma - Discontinued Products 146 Anaplastic Astrocytoma - Product Development Milestones 147 Featured News & Press Releases 147 Sep 26, 2016: Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer 147 Dec 07, 2015: Burzynski Research Institute Announces Favorable Objective Response Rates and Overall Survival in Adults with Anaplastic Astrocytoma Following Antineoplastons A-10 and AS2-1 147 Jun 18, 2015: Burzynski Research Institute Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma 148 Appendix 149 Methodology 149 Coverage 149 Secondary Research 149 Primary Research 149 Expert Panel Validation 149 Contact Us 149 Disclaimer 150
List of Tables
Number of Products under Development for Anaplastic Astrocytoma, H2 2017 9 Number of Products under Development by Companies, H2 2017 11 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 12 Number of Products under Development by Universities/Institutes, H2 2017 13 Products under Development by Companies, H2 2017 14 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15 Products under Development by Universities/Institutes, H2 2017 16 Number of Products by Stage and Target, H2 2017 18 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 19 Number of Products by Stage and Mechanism of Action, H2 2017 21 Number of Products by Stage and Route of Administration, H2 2017 23 Number of Products by Stage and Molecule Type, H2 2017 25 Anaplastic Astrocytoma - Pipeline by Advantagene Inc, H2 2017 26 Anaplastic Astrocytoma - Pipeline by Alfa Wassermann SpA, H2 2017 26 Anaplastic Astrocytoma - Pipeline by Amgen Inc, H2 2017 27 Anaplastic Astrocytoma - Pipeline by AngioChem Inc, H2 2017 27 Anaplastic Astrocytoma - Pipeline by Astellas Pharma Inc, H2 2017 28 Anaplastic Astrocytoma - Pipeline by Bayer AG, H2 2017 28 Anaplastic Astrocytoma - Pipeline by Boehringer Ingelheim GmbH, H2 2017 29 Anaplastic Astrocytoma - Pipeline by Burzynski Research Institute Inc, H2 2017 29 Anaplastic Astrocytoma - Pipeline by Cavion LLC, H2 2017 30 Anaplastic Astrocytoma - Pipeline by Celldex Therapeutics Inc, H2 2017 30 Anaplastic Astrocytoma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017 31 Anaplastic Astrocytoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017 32 Anaplastic Astrocytoma - Pipeline by Novartis AG, H2 2017 32 Anaplastic Astrocytoma - Pipeline by Orbus Therapeutics Inc, H2 2017 33 Anaplastic Astrocytoma - Pipeline by Pfizer Inc, H2 2017 33 Anaplastic Astrocytoma - Pipeline by Tocagen Inc, H2 2017 33 Anaplastic Astrocytoma - Pipeline by Tragara Pharmaceuticals Inc, H2 2017 34 Anaplastic Astrocytoma - Pipeline by TVAX Biomedical Inc, H2 2017 34 Anaplastic Astrocytoma - Pipeline by ZIOPHARM Oncology Inc, H2 2017 35 Anaplastic Astrocytoma - Dormant Projects, H2 2017 145 Anaplastic Astrocytoma - Discontinued Products, H2 2017 146



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify